All Whitepapers

For pharma companies engaged in digital transformation, LabVantage Pharma is a purpose-built, pre-validated LIMS to bring your labs along the transformation journey.

This whitepaper looks at the requirements for High Throughput Screening, High Content Screening and Surface Plasmon Resonance and makes suggestions for how to make these processes more flexible and repeatable.

This white paper describes how digitizing medicines can drive patient engagement, reduce non-adherence, and enhance supply chain visibility.

Life sciences transformations rarely fail because of what was in the plan. They fail because of what was not. Explore five trends that will determine their success in coming years.

Gain actionable insights from Lash Group experts, leveraging 30+ years of experience launching new programs to help you ensure patient support success.

In this case study, learn how to increase payer engagement, drive awareness, monitor competition, and leverage insights to enhance strategic plans and launch success.

With bigger patient access and affordability barriers given the new normal of COVID-19, see why field services are more important than ever. Read now.

This whitepaper discusses the importance of patient support programs and why a robust risk mitigation plan is critical to ensure that patients receive their therapy during crises.

In today’s fast-paced marketplace and complicated regulatory environment, operating in the life sciences industry can bring a variety of challenges. From raising capital or addressing pricing pressures to prioritizing development efforts or managing third-party risks, the landscape of Biopharma Finance is changing.

With the future of face-to-face field sales uncertain, how can pharma ensure product messaging reaches the right healthcare audiences and, ultimately, patients?

Hospitals represent a critical access point for many therapeutics. Whether a therapeutic is indicated for use exclusively in a hospital or in both inpatient and outpatient settings, hospitals are key points of drug initiation or switching. To gain access to this channel, pharma companies must understand the needs and differences of hospital systems.

Current safety reporting systems cannot meet the demands of a COVID-19 response. Find out how digital transformation enables rapid understanding & management of drug safety.

Virtual elements in clinical trials require extra considerations All teams involved should maintain ongoing dialogue and collaboration for success A discussion with industry leaders provides insight into such trials

An overview of marketing during the COVID-19 crisis and how to utilize various tactical solutions to successfully reach your targeted healthcare professional audiences.

LexisNexis Risk Solutions takes you inside the key considerations of making the all-important choice to partner with a data provider. Go beyond the well-polished sales pitches and understand the underlying implication of finding the right fit across 5 critical areas of business.

- Clinical trials can be designed across a continuum of formats. - Adding decentralized elements to trials can help acquire high-quality data. - Sponsors must understand the impact across the trial landscape for success.